Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,575 stopped studies mapped to Malignant Breast Neoplasm and descendants · 90% state a reason
Over the 1,575 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05239663 | GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early… | Phase 3 | terminated | Feb 15, 2022 | Sun Yat-sen University | Difficulty accruing subjects the study accrual was closed | Enrollment / accrual |
| NCT05068726 | Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients | — | terminated | Oct 6, 2021 | GE Healthcare | Sponsor discretion (low recruitment rate) | Enrollment / accrual |
| NCT05039931 | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or… | Phase 1 | withdrawn | Sep 10, 2021 | Sichuan Baili Pharmaceutical Co., Ltd. | leading entity of the clinical trial was replaced, and no patients were enrolled. | Enrollment / accrual |
| NCT06084676 | Organoid Model Predictive of Response to Immunotherapies | — | terminated | Oct 16, 2023 | Indiana University | difficulty recruiting participants | Enrollment / accrual |
| NCT04072393 | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | N/A | terminated | Aug 28, 2019 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT01855607 | Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy | Phase 2 | terminated | May 16, 2013 | Columbia University | Poor enrollment | Enrollment / accrual |
| NCT04120246 | Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | Phase 1 | suspended | Oct 9, 2019 | Veana Therapeutics | Study placed on hold. | Other (stated, no rule matched) |
| NCT02096588 | Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent… | Phase 2 | terminated | Mar 26, 2014 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The Principal Investigator left Johns Hopkins | Investigator |
| NCT03393741 | Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor… | — | terminated | Jan 8, 2018 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT00358098 | Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to… | — | terminated | Jul 28, 2006 | AHS Cancer Control Alberta | not stated | Not stated |
| NCT04862143 | Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast…(TELEPIK) | Phase 2 | terminated | Apr 27, 2021 | Novartis Pharmaceuticals | Study early terminated due to low enrollment compared to the anticipated figures | Enrollment / accrual |
| NCT02876640 | Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer | Phase 1 | terminated | Aug 24, 2016 | National Cancer Institute (NCI) | Inadequate Accrual Rate | Enrollment / accrual |
| NCT05163223 | Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer(Cornerstone001) | Phase 2 | terminated | Dec 20, 2021 | Aston Sci. Inc. | Difficulty in recruiting patients | Enrollment / accrual |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT04584775 | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care | N/A | withdrawn | Oct 14, 2020 | Medical University of Graz | Covid19 Pandemia | COVID-19 / pandemic |
| NCT04927884 | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast… | Phase 1 / Phase 2 | terminated | Jun 16, 2021 | ImmunityBio, Inc. | low enrollment | Enrollment / accrual |
| NCT00963547 | A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of… | Phase 1 | terminated | Aug 21, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01881880 | Value of Tomosynthesis in Breast Lesion Characterization and Breast Cancer Staging | N/A | terminated | Jun 20, 2013 | University Hospital, Montpellier | not stated | Not stated |
| NCT04619186 | Diffusion-Weighted MRI for Breast Cancer Screening in Women With a Personal History of… | — | suspended | Nov 6, 2020 | Seoul National University Hospital | Protocol setting | Other (stated, no rule matched) |
| NCT03199040 | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple… | Phase 1 | terminated | Jun 26, 2017 | Washington University School of Medicine | Drugs/equipment unavailable and insufficient funding | Funding |
| NCT02407613 | Efficacy of MR-HIFU Ablation of Breast Cancer | N/A | withdrawn | Apr 3, 2015 | UMC Utrecht | Patient recruitment was not feasible. | Enrollment / accrual |
| NCT04815291 | Streamlined Localization Using SCOUT® at Biopsy (STREAMLoc ) | N/A | terminated | Mar 25, 2021 | Merit Medical Systems, Inc. | Sponsor decision. | Sponsor / business decision |
| NCT05207514 | Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy… | Phase 3 | terminated | Jan 26, 2022 | Samyang Biopharmaceuticals Corporation | The Decision to Terminate Early Due to Difficulties in Recruiting Participants and Conducting the… | Enrollment / accrual |
| NCT04655573 | A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced… | — | terminated | Dec 7, 2020 | Duke University | requested by sponsor | Other (stated, no rule matched) |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | N/A | withdrawn | Sep 28, 2023 | The University of Tennessee, Knoxville | Unable to recruit participants | Enrollment / accrual |
| NCT05073172 | StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or… | N/A | withdrawn | Oct 11, 2021 | OHSU Knight Cancer Institute | study staff transition | Other (stated, no rule matched) |
| NCT01199367 | Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast… | Phase 1 | terminated | Sep 10, 2010 | Kyowa Kirin Co., Ltd. | The results of the dose escalation phase did not identify a well-tolerated dose that would permit… | Other (stated, no rule matched) |
| NCT05134194 | A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy… | Phase 3 | terminated | Nov 24, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Sponsor R \& D Strategy Adjustment\] | Sponsor / business decision |
| NCT04469205 | Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of…(OPTICOACH) | N/A | terminated | Jul 13, 2020 | Institut Curie | insufficient recruiting | Enrollment / accrual |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | Phase 1 | suspended | Jan 20, 2021 | DNAtrix, Inc. | DNAtrix management decision not based on study design, safety, or site performance. | Safety / toxicity |
| NCT02540330 | A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant(007) | Phase 2 | terminated | Sep 3, 2015 | Atossa Therapeutics, Inc. | Business decision (See Detailed Description) | Sponsor / business decision |
| NCT04136496 | Evaluation of a Novel Axillary Lymph Node Ink Localization Technique: A Feasibility Study | N/A | withdrawn | Oct 23, 2019 | The Ottawa Hospital | The study was never activated / began due to hospital staff and resources being re-allocated to… | COVID-19 / pandemic |
| NCT06137651 | Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of… | Phase 1 | withdrawn | Nov 18, 2023 | Northwestern University | Study terminated by the sponsor | Other (stated, no rule matched) |
| NCT03361800 | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage… | Early Phase 1 | terminated | Dec 5, 2017 | UNC Lineberger Comprehensive Cancer Center | Funding withdrawn. | Funding |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With… | Phase 1 | terminated | Oct 14, 2020 | Haihe Biopharma Co., Ltd. | Business decision | Sponsor / business decision |
| NCT05967286 | Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment… | Phase 2 | withdrawn | Aug 1, 2023 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT04172597 | A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human… | Phase 2 | terminated | Nov 21, 2019 | Spectrum Pharmaceuticals, Inc | Strategic business decision (unrelated to safety) | Safety / toxicity |
| NCT03841747 | Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast…(PELICAN) | Phase 2 | withdrawn | Feb 15, 2019 | Queen Mary University of London | Funding restrictions | Funding |
| NCT04102436 | Non-Viral TCR Gene Therapy | Phase 2 | withdrawn | Sep 25, 2019 | National Cancer Institute (NCI) | Difficulty with availability of GLP-grade reagents for manufacturing. | Drug supply |
| NCT01616758 | Phase II Study of GTx024 in Women With Metastatic Breast Cancer | Phase 2 | terminated | Jun 12, 2012 | GTx | not stated | Not stated |
| NCT05689359 | Evaluation of Hydroxychloroquine to Prevent CIPN | Phase 2 | withdrawn | Jan 19, 2023 | University of Arizona | Per Principal Investigator, it is not feasible to move forward with this trial. | Investigator |
| NCT03709082 | Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2… | Phase 1 / Phase 2 | terminated | Oct 17, 2018 | University of Kansas Medical Center | Low accrual | Enrollment / accrual |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT04199520 | Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy… | Phase 2 | withdrawn | Dec 16, 2019 | Henan Cancer Hospital | In clinical treatment, most patients with stage IV breast cancer received surgical treatment, which… | Enrollment / accrual |
| NCT04770714 | Prospective Comparison of Breast MRI vs Contrast Mammography Prior to Surgery in Breast… | N/A | withdrawn | Feb 25, 2021 | University of Arizona | No Participants enrolled. | Enrollment / accrual |
| NCT05703555 | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701(INTRUSION) | Phase 2 | withdrawn | Jan 30, 2023 | Erasmus Medical Center | Due to the decision to discontinue the global clinical development program of tusamitamab ravtansine | Other (stated, no rule matched) |
| NCT05065411 | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of…(VERU-024) | Phase 3 | terminated | Oct 4, 2021 | Veru Inc. | Business decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 1, 2024source: clinicaltrials